NovaBridge Biosciences (NBP) Common Equity (2018 - 2026)

NovaBridge Biosciences (NBP) has reported Common Equity for 8 consecutive years, with $230.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Common Equity rose 14.8% year-over-year to $230.9 million; the TTM figure through Dec 2025 stood at $230.9 million (up 14.8% YoY), while the FY2025 annual figure was $230.9 million, up 14.8% from the prior year.
• Common Equity eased to $230.9 million in Q4 2025 per NBP's latest filing, from $258.9 million in the prior quarter.
• Across five years, Common Equity topped out at $713.2 billion in Q4 2021 and bottomed at $196.7 million in Q2 2025.
• Historically, Common Equity has averaged $55.2 billion across 5 years, with a median of $238.6 million in 2023.
• Annual changes were most pronounced in 2021 — Common Equity jumped 83890.13% — and 2022, when it plunged 99.94%.
• NovaBridge Biosciences' Common Equity stood at $713.2 billion in 2021, then slumped by 99.94% to $409.1 million in 2022, then sank by 41.68% to $238.6 million in 2023, then fell by 15.7% to $201.2 million in 2024, then climbed by 14.8% to $230.9 million in 2025.
• Business Quant data shows NBP's Common Equity at $230.9 million in Q4 2025, $258.9 million in Q3 2025, and $196.7 million in Q2 2025.